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In 1995, the American Society of Human Genetics (ASHG) and American College of Medical Genetics and Genomics (ACMG) jointly
published a statement on genetic testing in children and adolescents. In the past 20 years, much has changed in the field of genetics,
including the development of powerful new technologies, new data from genetic research on children and adolescents, and substantial
clinical experience. This statement represents current opinion by the ASHG on the ethical, legal, and social issues concerning genetic
testing in children. These recommendations are relevant to families, clinicians, and investigators. After a brief review of the 1995 state-
ment and major changes in genetic technologies in recent years, this statement offers points to consider on a broad range of test tech-
nologies and their applications in clinical medicine and research. Recommendations are alsomade for record and communication issues
in this domain and for professional education.Introduction
In 1995, the American Society of Human Genetics (ASHG)
and American College of Medical Genetics and Genomics
(ACMG) published a joint statement titled ‘‘Points to
Consider: Ethical, Legal, and Psychosocial Implications of
Genetic Testing in Children and Adolescents.’’1 This publi-
cation was influential in guiding clinicians and families
during an era in which a number of new genetic tests,
particularly predictive or predispositional testing, were be-
ing introduced into clinical medicine. Since 1995, clini-
cians have gained substantial experience with genetic
testing in a number of clinical contexts, and research has
improved the evidence on which professional recommen-
dations can be developed. The ASHG determined that a
new statement addressing genetic testing in children was
timely, both because of the continuing evolution of ge-
netic testing and because of the special considerations
raised in the care of children. The purpose of this state-
ment is to provide guidance on a variety of different ge-
netic testing approaches for children in both the research
and clinical contexts.
The ethical, legal, and social issues in genetic and
genomic testing have been subject to special scrutiny for
several reasons. First, for some heritable conditions, ge-
netic testing can provide powerfully predictive informa-
tion about the individual’s future health status. Profes-
sionals, and society more broadly, have been concerned
about the impacts of such predictive power on the psycho-
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genetic information about one individual provides pre-
sumptive information about other ‘‘blood’’ relatives. The
family or kindred nature of genetic information poses
ethical, legal, and social challenges for the appropriate
management of that information in clinical and research
contexts. Third, genetic and genomic information is com-
plex, and health risks associated with this information are
often probabilistic. This means that special care and exper-
tise are important in ordering and interpreting many ge-
netic tests. Finally, genetics has a troubled history, evident
during the first half of the twentieth century, when ge-
netic concepts were misunderstood and misused to the
detriment of vulnerable groups in society. Genetic and
genomic tests are not uniquely challenging with respect
to ethical, legal, or psychosocial considerations, but these
features justify careful thought and an element of caution
as we assess the benefits and risks of these evolving
technologies.
This statement is focused on the use of these technol-
ogies with children. Children also warrant special consid-
eration for several reasons. Informed consent to genetic
and genomic testing is a core principle for which there
are few exceptions. Young children lack decision-making
capacity, so decisions about testing must be conducted
through surrogates, usually the parents, and must be
done with the child’s best interest at heart. The notion
of ‘‘best interest’’ is intended to place the child’s welfare
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subjective nature of the interests of those who cannot
speak for themselves, defining an individual child’s
‘‘best interest’’ is often complex and controversial, partic-
ularly in medical circumstances involving burdensome
treatments and profound disabilities. Surrogate decision
making is also an ethically freighted concept, because
although parents are the appropriate surrogates for their
children in almost all cases, controversies arise when par-
ents make decisions that seem contrary to the best inter-
est of their child.
As children age, they gain decision-making capacity and
experience with health conditions. Therefore, including
children to various degrees as they age in genetic- and
genomic-testing decisions and responses is important but
challenging. Finally, because children are young, decisions
for them, and by them, might have implications for the
course of their lives.
As genetic and genomic tests become more accurate and
their use becomes more common, these ethical, legal, and
psychosocial challenges will becomemore familiar and less
worthy of statements of this sort. In many contexts, ge-
netic and genomic tests are no different than other forms
of testing. But in the contexts outlined below, the ASHG
believes that these recommendations will assist families,
clinicians, investigators, and policy makers in maximizing
the benefits offered by these evolving forms of genetic and
genomic testing.
A Summary of the 1995 ASHG Report
In 1995, the ASHG and ACMG issued a joint report that
offered points to consider for genetic testing in children.
The clinical context of that report focused on decisions
about testing for single-gene disorders in response to
either a family history or within-population screening
programs. The social context of that report included
limited data about the psychosocial impact of such
testing in children. The ASHG and ACMG recommended
that clinicians and parents consider timely medical ben-
efits related to diagnosis, prognosis, and interventions as
the best justification for testing in the child. Addition-
ally, the report recommended that the potential psycho-
logical benefits to adolescents who request such testing
also be considered. The report suggested that in the
absence of timely medical benefits to the child, or the ex-
pressed wishes of adolescents, testing should be deferred
until adulthood, particularly for adult-onset conditions
or for carrier status for reproductive decision making.
However, the report acknowledged that there was limited
information about the benefits and risks of genetic
testing in children. The report recommended deferral of
testing in the face of this uncertainty, yet it also recom-
mended deference to parents in some circumstances.
The report has been influential in encouraging caution
and reflection regarding testing children but often has
been over-interpreted as a stricter prohibition of predic-
tive testing in children for adult-onset conditions than
was intended.Recent Changes in Genetic and Genomic
Technologies
Cytogenetics and molecular diagnostics have both under-
gone several revolutions since the fields began in 1959
and in1976, respectively.2,3Cytogenetics startedwith chro-
mosome analysis and matured with increasingly detailed
banding and then fluorescence in situ hybridization. Most
recently, the field has seen the introduction of chromo-
somalmicroarray analysis (CMA) for deletions and duplica-
tions (formerly done by cytogenetics). Molecular diagnos-
tics has transitioned from hybridization-based techniques
to Sanger sequencing with the increasingly common utili-
zation of next-generation-sequencing-based techniques.
In both fields, the increased coverage and increased resolu-
tion of the current technologies confer high analytic valid-
ity, but both platforms create problemswith interpretation.
First, a significant challenge is the difficulty in distinguish-
ing between pathogenic variants and rare polymorphisms,
resulting in the identification of ‘‘variants of uncertain sig-
nificance.’’ Second, there are difficulties in interpreting var-
iants and copy-number alterations whose significance is
incompletely understood because of reduced penetrance
or a lack of sufficient data on clinical associations. Third,
these technologies result in the identification of variants
unrelated to the indication for testing (secondary or inci-
dental findings). These challenges arise from our evolving
understanding of the fine structure and variation in the hu-
man genome. At the present time, the contrast between our
ability to identify genetic variants and our ability to fully
interpret the information gives rise to many of the ethical
issues in this domain.
Predictive Genetic Testing in High-Risk Families
In the 20 years since the first ASHG-ACMG pediatric-
testing statement, there has been a modest volume of clin-
ical research about the impact of predictive testing in high-
risk families. To date, this limited research has not found
evidence of significant psychosocial harms in children.4
Perhaps the most significant finding is that, even without
testing, children andmany families create narratives about
a child’s genetic status. That is, some families simply as-
sume that their children are destined to have, or not
have, the familial condition. Further, the baseline uncer-
tainty about risk status can cause psychosocial distress in
the absence of genetic testing. Over the last two decades,
there has been a general shift toward greater parental
discretion in the face of clinical uncertainty about the
best interests of the child.5 This broad shift is not exclusive
to genetics but has implications for genetic testing.
As parents consider the best course of action regarding ge-
netic testing of their children, it remains important for par-
ents to be aware that informed adults make a range of
choices about predictive and reproductive testing, and
thus many adults decline such testing. Deferring testing
to adulthood allows children the opportunity tomake their
own decisions. This is especially important for the small
subset of conditions where a minority of at-risk adults optThe American Journal of Human Genetics 97, 6–21, July 2, 2015 7
for genetic testing, such as for Huntington disease. Ap-
proaching parents (and children, when appropriate) with
respectful but directive recommendations, along with
acknowledging flexibility, might be an effective approach
to forging a therapeutic alliance with families. Encouraging
families to consider such decisions over a period of time
might convince some families that testing will be helpful
in their particular context, or it might become clear that it
will be most appropriate to defer testing until adulthood.
The ASHG offers the following recommendations:
d Unless there is a clinical intervention appropriate in
childhood, parents should be encouraged to defer
predictive or pre-dispositional testing for adult-onset
conditions until adulthood or at least until the child
is an older adolescent who can participate in decision
making in a relatively mature manner.
d Adolescents should be encouraged to defer predictive
or pre-dispositional testing for adult-onset conditions
until adulthood because of the complexity of the po-
tential impact of the information at formative life
stages.
d Providers should offer to explore the reasons why
parents or adolescents are interested in predictive or
pre-dispositional testing for adult-onset conditions.
Providers can acknowledge that, in some cases,
testing might be a reasonable decision, but decisions
should follow thorough deliberation.
Adolescents should be provided the opportunity to
discuss these issues without the presence of their parents,
although parents should be involved in, and supportive
of, any final decisions for testing. A referral to genetic
counselors and mental-health professionals is appropriate
if the clinician and family need additional support for de-
cision making or in assessing the psychosocial dynamics.
d Facilitating predictive or pre-dispositional testing of
children for adult-onset conditions can be justified
in certain circumstances. For example, after careful
deliberations with the family and older child, testing
can be justified to alleviate substantial psychosocial
distress or to facilitate specific life-planning decisions.
The impact of predictive testing on children and fam-
ilies remains uncertain and therefore can be justified
in specific cases when it is requested by families after
informed deliberations and when the testing is not
clearly inconsistent with the welfare of the child.
d Empirical research on the psychosocial impact of pre-
dictive or pre-dispositional testing in children is
necessary for future policy recommendations. Ge-
netic testing of children for adult-onset conditions
in the research context can be ethically justified
because of its social importance and when risks are
minimized by appropriate counseling and support
and when appropriate parental permission and child
assent are obtained.8 The American Journal of Human Genetics 97, 6–21, July 2, 2015Genome-Scale Sequencing in Children
The technology to enable whole-exome sequencing and
whole-genome sequencing has become more accurate,
more efficient, and less expensive. For the purposes of this
statement, we use the term ‘‘genome-scale sequencing’’ to
mean either whole-genome or whole-exome sequencing.
The cost of genome-scale sequencing is coming down pro-
gressively, and there is some confidence that ‘‘the $1,000
genome’’ will be achieved in the next few years. These
cost estimates are for the generation of sequence data and
do not include the clinical interpretation of the informa-
tion. Given these technical improvements, genome-scale
sequencing can be considered in a variety of clinical and
research contexts. These include diagnostic testing, predic-
tive testing for childhood-onset conditions, pharmacoge-
netic testing, and testing in children with cancer to inform
diagnosis or therapy.
Genome-scale sequencing creates a tension between the
need togenerate a comprehensiveanalysisof an individual’s
genome to address a clinical challenge and the need to limit
problems created by a wealth of data, including secondary
findings and findings of uncertain clinical significance.
Yet, the improving coverage, accuracy, sensitivity, and cost
effectiveness of genome-scale sequencing will eventually
equal that of testing a single gene or performing targeted
gene panels, meaning that genome-scale sequencingmight
become an attractive choice for interrogating a single gene
or targeted set of genes. The ASHG recognizes the current
debate regarding the obligation, if any, to search for selected
variants with high clinical validity and clinical utility when
conductinggenome-scale sequencing.6TheASHGmakes an
important distinction between using genome-scale
sequencing as the method of choice for searching broadly
for a diagnosis and choosing genome-scale sequencing
with analysis restricted to a limited number of genes when
amore targeted strategy is indicated. The recommendations
below reflect ASHG’s assessment that targeted tests, or selec-
tive sequence analysis, is usually preferable to less-discrimi-
nate data acquisition when the clinical challenge can be
addressed through a targeted approach.
d When clinically indicated, the scope of genetic
testing should be limited to single-gene analysis or
targeted gene panels based on the clinical presenta-
tion of the patient.
d Targeted testingusinggenome-scale sequencing,but re-
stricting analysis to a limited set of genes relevant to the
clinical indication, is an acceptable alternative to a
single-gene analysis or targeted gene panel in certain
circumstances. When genome-scale sequencing is per-
formed but the analysis is restricted to a limited set of
targeted genes, ASHG finds it ethically acceptable for
the laboratory to limit the analysis to the genes of clin-
ical interest.
d ASHG recommends that, in the context of diagnostic
testing for a child with a most likely genetic disorder,
genome-scale sequencing is appropriate when prior,
more limited genetic testing failed to identify a caus-
ative mutation. Depending on the clinical presenta-
tion and on the quality and availability of appropriate
targeted testing, comprehensive testing such as
genome-scale sequencing might also be indicated in
certain circumstances, even in the absence of prior,
more limited genetic testing.
d At the present time, genome-scale sequencing is not
indicated for screening in healthy children. Accord-
ingly, genome-scale sequencing is not indicated for
the purposes of clinical newborn screening at this
time. In the research setting, genome-scale sequencing
in newborns for screening purposes can be justified as
part of carefully developed protocols for better under-
standing the potential benefits and risks of this tech-
nology in this context.Secondary Findings
The move from targeted genetic testing to genome-scale
sequencing has led to a vigorous debate about the ethics
of managing massive amounts of individual-level genetic
data.7 (It should also be noted that although secondary
findings are a significant problem for genomic medicine,
they are by nomeans unique to this field; other disciplines,
particularly radiology and pathology, have been grappling
with similar concerns for decades. See, e.g., Berland et al.8
and Orme et al.9) The generation of a patient’s genomic
sequence data radically increases the probability of discov-
ering incidental or secondary findings.10 For consistency,
throughout this statement we use ‘‘secondary findings,’’
defined as clinically relevant information unrelated to the
condition for which the sequencingwas originally ordered.
Secondary findings might have a clinical utility for a
child or his or her family members. Therefore, there will
be cases in which it is acceptable to return Clinical Labora-
tory Improvement Amendments (CLIA)-validated infor-
mation derived from a child’s sequence when such infor-
mation has important clinical implications for the child
or someone in the child’s family.
Parents or guardians should have a clear understanding
of when secondary findings might be generated and of
the circumstances, if any, under which they can expect
to be offered results. Children should be included in the
informed-assent or -consent process to the extent that
they are capable.
d ASHGrecommends that cliniciansoffer todisclose sec-
ondary findings for a child to the child’s parents or
guardiansonlywhen the informationhas clear clinical
utility for the child and/or his or her family members.
d In any clinical genomic endeavor that has a substan-
tial likelihood of generating clinically relevant sec-
ondary findings, ASHG recommends that there
should be a robust informed-consent process.
d If genome-scale sequencing is performed in somatic
tissue, such as in tumor tissue in children with cancer,it is usually necessary to also conduct germline
sequencing on the patient to adequately interpret
the tumor sequence.11 Therefore, ASHG recommends
that the same considerations in the management of
secondary findings be undertaken for both somatic-
tissue sequencing and germline genome-scale
sequencing.
Parents have wide decision-making authority, but in
cases where the clinical response to a secondary finding
will most likely prevent serious morbidity or mortality
for the child, it can be appropriate to override a parental
decision not to receive this information.
d ASHG recommends that, in general, parents should
be able to decline to receive secondary findings in
advance of genetic testing.
d However, when there is strong evidence that a sec-
ondary finding has urgent and serious implications
for a child’s health or welfare, and effective action
can be taken to mitigate that threat, ASHG recom-
mends that the clinician communicate those findings
to parents or guardians regardless of the general pref-
erences stated by the parents regarding secondary
findings.
There is an ongoing debate about the extent to which re-
searchers are obligated to disclose secondary findings to
research participants. Research and clinical care have
distinct characteristics, and the responsibility of a clinician
necessarily differs from that of a researcher.12 Clinicians
have a primary obligation to act in the best interest of their
patient; researchers must protect the welfare of subjects
but are primarily charged with the production of generaliz-
able knowledge. Although they are generally distinct, the
line between research and clinical care is often blurry,
particularly in the context of genomics.13 Institutional re-
view boards (IRBs), perhaps with expert consultation, are
in the best position to determine whether and how to
disclose secondary findings in a given research setting.
d When secondary findings are likely to be generated in
the conduct of pediatric research, ASHG recommends
that investigators develop and follow an IRB-
approved plan to manage such findings.
Questions about whether there is a duty to look for sec-
ondary findings have been actively debated.6 As analytic
tools make searching for a limited list of high-value vari-
ants more efficient, the benefits of actively searching for
such variants in the clinical context are likely to outweigh
the costs and adverse consequences. However, more data,
experience, and debate are necessary for defining the
most ethically appropriate approach in the clinical pediat-
ric context regarding an obligation to look for secondary
findings. In the research context, the ethical responsibil-
ities and risk-benefit considerations differ from the clinicalThe American Journal of Human Genetics 97, 6–21, July 2, 2015 9
context. Therefore, actively searching for secondary find-
ings in research involving genome-scale sequencing might
be ethically acceptable in certain circumstances (with the
informed consent of parents) but should not be considered
ethically required at the present time.7,14
d In the clinical and research contexts, ASHG recom-
mends that it be considered ethically acceptable, but
not required, to search for secondary findings that
are not relevant to the clinical or research indication
for sequencing.CMA
The transition from chromosome analysis by karyotype to
the utilization of CMA has transformed genetic diagnos-
tics.15 CMA is now a standard diagnostic test for a wide va-
riety of conditions, including developmental delay with
and without dysmorphic features, autism spectrum disor-
ders, and multiple congenital anomalies, in the pediatric
population.16 Use of these arrays has increased the utility
of cytogenetic testingby increasing the rate of positive diag-
noses (allowing the identification of much smaller dele-
tions and duplications than cytogenetics alone), and with
increasinglyprecise definitionof breakpoints andgene con-
tent for deletions and duplications, it has allowed the iden-
tification of many new syndromes.17 However, these tests
also allow the identification of copy-number alteration of
disease-associated genes unrelated to the initial reason for
study, allow the identification of excessive homozygosity
indicatingpotential consanguinity or incest, andhave a sig-
nificant likelihood of identifying a variant of uncertain sig-
nificance. CMA also has the potential to identify secondary
findings. Therefore, CMA, like sequencing, raises ethical
considerations that warrant obtaining informed consent
fromthe child’s parents, a practice thathasnotbeen routine
for traditional chromosome analysis.
d The ASHG recommends that work be conducted for
assembling a list of genes in which duplications or de-
letions are clearly associated with clinically important
diseases. This list could function as a secondary-find-
ings list with implications for what should and
should not be reported back to families.
d Clinicians and parents should be adequately
informed about the complexities of CMA testing
before CMA testing is ordered and results are provided
to patients. Clinicians should understand the con-
cepts of variants of uncertain significance, variable ex-
pressivity, and reduced penetrance and the potential
need to consider testing of other family members.
d The ASHG recommends that practice guidelines be es-
tablished for using CMA testing.Carrier Testing of Adolescents
Carrier testing of adolescents has historically been contro-
versial, and professional statements generally do not sup-10 The American Journal of Human Genetics 97, 6–21, July 2, 2015port routine carrier testing of adolescents outside of
pregnancyor reproductive planning.18,19Hypothetical con-
cerns include stigma, discrimination, and potential confu-
sion over affected versus carrier status.4 It is notable that a
significant body of literature addresses carrier screening in
adults. Outside of some specific populations (e.g., Orthodox
Jewish individuals), there is little documentation of discrim-
ination around carrier status in recent years, andmost adult
carriers without a family history do not appear to have sig-
nificant short- or long-term differences in anxiety. In
contrast, adult siblings of individuals affected by recessive
or X-linked conditions often have strong views on whether
or not they wish to know their carrier status and how it
might affect their reproductive decision making. Some
studies have reported that siblings show transient anxiety
and depression after carrier testing.20–23
Most studies assessing adolescent or childhood carrier
testing are small and address individuals with a family
history of X-linked conditions (e.g., Duchenne muscular
dystrophy, hemophilia, and fragile X syndrome) and auto-
somal-recessive conditions; Borry et al. provide a summary
of some of the early literature in this area.18,24 These small
studies documented high short-term recall and a number
of potentially beneficial psychosocial outcomes, including
relief in those who are non-carriers, relief from uncertainty
in both carriers and non-carriers, and positive reappraisal
of self-esteem and self-image. Additionally, these studies
also suggested that adolescents found to be carriers felt
able to plan for future parenthood and that most were
open about the condition and their carrier status, sharing
with family, and planning to tell partners.25–29
d On the basis of the evidence indicating potential
benefits and a low risk of harm, ASHG neither recom-
mends nor discourages offering carrier testing to ado-
lescents who desire such testing in the setting of a
positive family history. Adolescent assent and
parental consent should be obtained for carrier
testing, and genetic counseling might be appropriate
in some circumstances.
Carrier testing could be performed on children in other
less well-studied settings, including institutional settings
such as high school, college, or athletic programs.
Outcome studies in this area are somewhat limited and
generally describe carrier testing offered in high schools
in Canada, Australia, and the Netherlands. These studies,
performed over 20 years, have shown high uptake rates
and have not demonstrated adverse psychological conse-
quences.30,31 Ross summarizes many of these early studies
and discusses potential concerns—including those about
potential coercion, confidentiality, and the informed-con-
sent process—with similar implementation in the US.32
d ASHG recommends that carrier testing in children
and adolescents not be performed through institu-
tional or population-based approaches at this time.
Research projects to further evaluate adolescent car-
rier testing in institutional contexts is appropriate
with carefully drafted protocols.Direct-to-Consumer Testing
Direct-to-consumer genetic testing (DTC GT) refers to ge-
netic testing that bypasses the involvement of health-
care providers and is sold directly to consumers. DTC GT
is marketed to consumers primarily via the internet and
was initially limited to paternity and ancestry testing.
However, DTC GT has in recent years been expanded to
offer testing for potential health-related claims.33 Several
concerns have been raised about DTCGT, and they include
the lack of high-quality pre-test and post-test counseling
and clinical interpretation of test results, the lack of
adequate validation of some tests, and the testing of chil-
dren for adult-onset conditions.
DTCGToffers individuals the opportunity to have access
to personal genetic information.34 Yet, there is a strong
tradition in genetics that in many clinical circumstances,
testing involves pre- and post-test counseling from a quali-
fied health-care provider, meaning a genetic counselor or a
medical geneticist.35 It is clear that someclinicianswhopro-
vide genetic-risk assessment of DTC GT results to patients
lack the knowledge or background for appropriate interpre-
tation. In one studyof interviews conductedwith clinicians
who offered genomic-risk assessment to patients, the clini-
cians appeared to have learned most of what they know
about genomics directly from the commercial labora-
tories.36 In the absence of professional counseling and
interpretation, there are concerns that consumers might
make misguided changes in their health care or lifestyle.37
Fortunately, empiric studies of DTCGT to date have shown
little or no evidence of inappropriate changes in lifestyle or
health-related behaviors.38–46
DTC GT provides information of variable accuracy and
clinical validity.47 Some companies that offer DTC GT
have made poorly validated claims regarding the health
impact of their testing. In response to such marketing
claims, the FDA prohibited 23andMe from selling its per-
sonal-genome service in November 2013.48 However, this
does not prevent overseas companies from marketing or
providing services or US-based companies from moving
overseas.49 It also does not prevent companies from offer-
ing genetic testing services without associated clinical
interpretation. Other countries have passed legislation
that regulates DTC GT.50
DTC GT has additional implications in children, given
that many of these tests are intended to diagnose or iden-
tify risk for adult-onset disorders, such as breast cancer,
ovarian cancer, and Huntington disease. One study sur-
veyed companies that offer DTC GT, and only 13 re-
sponded. Ten of those 13 companies performed testing of
minors in response to requests from parents or legal guard-
ians. Three companies would consider testing if it was re-
quested by a minor.51TFinally, there is no consistency regarding the informa-
tion provided on DTC GT websites regarding consent for
testing. Information on DTC GT websites might not be
balanced with regard to how they present risks and bene-
fits. Users of the test might consent to testing without un-
derstanding the full consequences of the results.52,53
d The ASHG recommends that DTC GT be discouraged
in children until such a time when companies that
provide DTC GT can assure quality, accuracy, and val-
idity of their testing and assure that there is adequate
pre- and post-testing counseling.
d The ASHG recommends that DTC GT in children be
performed with the appropriate informed permission
from a parent or legal guardian and the assent of the
child when appropriate.
d The ASHG recommends that DTC GT not be per-
formed in children for genetic conditions that have
onset in adulthood or require surveillance beginning
in adulthood.Pharmacogenomic Testing
Pharmacogenetic testing in adults and in children has the
potential to improve drug efficacy and reduce adverse
events.54 Testing might be indicated prior to the first use
of a medication in order to guide drug choice and initial
dosing or to evaluate adverse effects or non-responsiveness
to prior drug treatments. However, research on pharmaco-
genetic testing in children has been limited, so there is little
current evidence on the potential benefits and harms asso-
ciated with this type of genetic testing. Further, pharmaco-
genetic data can account for some, but not all, variability in
drug response and therefore should be considered in
conjunction with other factors in clinical pharmacologic
decision making. In particular, some enzymes known to
have significant pharmacogenetic variability can be ‘‘meta-
bolically immature’’ in newborns and infants.55,56 This can
result in clinical outcomes that are different from those pre-
dicted by genotype alone. CYP2C19, an enzyme that is
involved in a number of commonly prescribed drugs, is
one example in which genotypically predicted extensive
(normal) metabolizers can have a poor metabolizer pheno-
type in the first few months of life.57
Clinical pharmacogenetic testing in children is strongly
supported by evidence in some areas, such as TPMT testing
in association with thiopurine therapy for childhood leu-
kemia. Pharmacogenetic testing has been proposed for
clinical use and is supported by varying levels of evidence
in many medical specialties, including but not limited to
oncology, rheumatology, psychiatry, HIV treatment,
immunosuppression, and anticoagulation.54–56,58–62
d ASHG recommends that when there is a clear
evidence base in the literature for clinical utility, phar-
macogenetic testing in children might be appro-
priate.he American Journal of Human Genetics 97, 6–21, July 2, 2015 11
12d ASHG recommends additional evaluation of pharma-
cogenetic testing opportunities in the pediatric popu-
lation in order to better demonstrate the utility and
limitations of this form of testing.Newborn Screening
Newborn screening (NBS) is one of the most effective pub-
lic-health programs of the last century. The ASHG strongly
supports NBS programs and encourages genetic profes-
sionals to support NBS in their communication with pa-
tients, colleagues, and policy makers.
NBS is conducted by state-based public-health programs
in the US. For the first four decades of the programs, there
was substantial variability between states on the condi-
tions targeted.63 In 2005, the ACMGpublished recommen-
dations for a uniform panel composed of 29 primary con-
ditions and a number of secondary conditions that will be
identified through targeting the primary conditions.64
These recommendations were supported by the American
Academy of Pediatrics and the newly formed Secretary’s
Advisory Committee on Heritable Diseases in Newborns
and Children (SACHDNC).
The SACHDNC was established in 2004 through federal
legislation with the primary goal of establishing an evi-
dence-review process to make recommendations for condi-
tions on a uniform screening panel.65 Although states
determine thenature of their screeningprograms, currently
all states screen for all conditions on the ACMG list.
Given the low prevalence of most conditions targeted by
NBS, making informed policy decisions regarding the
introduction of new tests is challenging. For this reason,
the ASHG supports robust evidence-review processes, at
the state and/or federal level, as an essential element to a
state health department’s policies and procedures for NBS
programs.
d The ASHG recommends that state programs only
introduce new conditions on a mandated NBS panel
after a thorough review of the evidence on the
benefits and harms, the impacts on systems of care,
resources, and capacity, and input from relevant
stakeholders.
State NBS programs are designed to both enable affected
children to receive a prompt, accurate diagnosis and coor-
dinate short-term clinical care for the condition. However,
health departments do not typically collect data on the
longer-term outcomes for children or their families.
Further, the low prevalence of many conditions targeted
through NBS makes it difficult to conduct outcomes
research without large, multicenter projects. Therefore,
data on the clinical outcomes of affected children, with
or without NBS, is often limited.
d The ASHG supports conducting outcomes research on
NBS and developing infrastructures for conductingThe American Journal of Human Genetics 97, 6–21, July 2, 2015outcomes research on these rare conditions. Such in-
frastructures would support the ability to assess out-
comes and to conduct controlled trials of therapeutic
options and evaluate support systems required for
affected children and their families.
NBS is conducted on dried bloodspots collected from the
infant within the first few days of life. Although all state
programs provide information to parents about NBS, usu-
ally in the form of a brochure, the literature shows that
most parents do not read this information. Accordingly,
most parents have little awareness and understanding of
NBS.66 The literature also demonstrates that many pri-
mary-care physicians (PCPs) have a limited understanding
of NBS and often feel poorly prepared to manage screen-
positive infants and provide guidance to their parents.67
Adequate information and education of parents and
PCPs is important for maximizing the effectiveness of
these programs. The literature demonstrates that parents
want to be informed, but most only want basic facts about
NBS programs.66 However, research has been limited on
how to effectively deliver information to parents about
NBS. Public surveys, the American Academy of Pediatrics,
the American College of Obstetrics and Gynecology, and
commentators support NBS education in the prenatal
time period.68
d The ASHG recommends additional research for
improving the quality, delivery, and effectiveness of
parental, public, and professional education
regarding NBS.
NBS is conducted under state mandates in all but two US
states or territories (Wyoming and the District of
Columbia). However, 43 states permit parents to refuse
NBS for either religious or philosophical reasons. The num-
ber of parents who opt out of NBS is exceedingly small.69,70
The role of parental permission in the conduct of NBS
has been a topic of debate since the inception of the pro-
grams in the 1960s. State programs typically are strongly
supportive of the current opt-out approach because a
formal permission process is cumbersome, particularly if
signed consent forms are required, and could increase the
risk that newborns will not be screened. Nevertheless, a
number of professional statements over the years support
a parental permission process (an ‘‘opt-in’’ approach).19,71
Surveys of public and professional attitudes regarding
parental permission demonstrate that the public is evenly
split on the appropriateness of opt-in versus opt-out ap-
proaches.72,73 However, the public expects to be informed
about NBS regardless of the permission model.
Obtaining truly informed permission for NBS during the
postnatal period is challenging because of the hectic envi-
ronment, the short hospitalization for many newborns,
and the many competing priorities for parents and
newborn-care providers. Further, signatures to document
permission can be obtained in a perfunctory fashion, so
requiring signatures per se does not assure a meaningful
informed-permission process. Under the assumption that
parents are reasonably informed about the program and
their rights under state law, both opt-in and opt-out ap-
proaches to NBS are ethically acceptable.
d Although the ASHG supports improved parental edu-
cation about NBS, it does not advocate a change in
most state programs that mandate screening but
permit parental refusals.
When screening is conducted, programs obtain suffi-
cient blood from infants to perform all testing and to
conduct repeat testing when warranted. This means that
most infants will have extra blood on the filter cards after
screening. Traditionally, many states have saved these re-
sidual dried bloodspots (DBSs) for several purposes,
including quality assurance (QA) for NBS laboratory ser-
vices, forensic uses, and biomedical research.63 The DBSs
are particularly useful for research because they represent
a tissue set on the entire population of newborns and
can be used for genetic epidemiology and for exposure to
prenatal infectious diseases and environmental toxins,
among other applications. Although many states discard
the DBSs after screening is complete, many states retain
these DBSs for various lengths of time. The retention of
DBSs became controversial in recent years when two state
programs, those of Minnesota and Texas, were sued by
parent groups for the lack of parental permission for this
practice.
In the US and Canada, research on public attitudes
regarding the management of DBSs demonstrates broad
public support for the retention of DBSs for QA and
biomedical research, contingent on parental education
and choice.72,74 Consistent with public and professional
opinions on this issue, the ASHG supports the retention
and research uses of residual DBSs under carefully devel-
oped, transparent public policies and practices. Prior to
2015, when used for biomedical research, residual DBSs
were typically de-identified, or research was conducted un-
der a waiver of parental permission. However, in late 2014,
the Newborn Screening Saves Lives Reauthorization Act of
2014 (public law no. 113-240) was passed to require
informed consent from parents for all Department of
Health and Human Services-funded research using DBSs
and to prohibit the waiver of consent. The impact of this
law on NBS-related research remains to be determined.
However, the ASHG considers the retention of DBSs strictly
for quality-improvement activities for the NBS programs to
be covered under the state mandate for screening. There-
fore, parental permission should not be necessary for the
use of DBSs for QA purposes.
d The ASHG encourages states to retain DBSs for QA
purposes. Retention for QA purposes should be
considered integral to the NBS program and should
not require specific permission from parents.Td The ASHG encourages states to retain DBSs and to
make specimens available to investigators and to pub-
lic-health programs under carefully developed guide-
lines.
d Parents should be informed of state policy and prac-
tices regarding the retention and use of DBSs.75
d Parents should be offered a choice regarding the
retention and use of their child’s DBSs for purposes
beyond the clinical NBS program and QA uses. This
choice ought to be clearly separated from the decision
to participate in NBS.
NBS can also provide benefits to a newborn’s family by
alerting parents to their reproductive risk for future preg-
nancies and can benefit societymore broadly by advancing
the understanding of disease. Information relevant to
reproductive risk is also provided by the generation of re-
sults related to carrier status. Disclosure of carrier status
through NBS raises challenges because this information is
not typically available without informed consent and is
not usually provided to minors.76–78 However, recent
guidelines and studies have suggested that reproductive
benefits might represent an important goal of NBS because
carrier detection can inform family planning.79–82 Many
NBS programs disclose carrier results to families. However,
there is limited evidence to support the utility and impact
of disclosing carrier results to families. A stronger eviden-
tiary base is required to inform evidence-based decision
making and recommendations.
d The ASHG recommends additional research for assess-
ing the utility of disclosing carrier results generated
from NBS for reproductive decision making and
cascade testing, as well as the impacts on systems of
care and resources in the context of engagement
with relevant stakeholdersAdoption, Consanguinity, and Paternity
Adoption
In the US, approximately 2% of children are adopted, and
many children are living in foster care. Prospective adop-
tive parents might want genetic information about a child
to inform their decision on whether or not to adopt. But
previous consensus statements of the ASHG and ACMG
have advocated that indications for pre-adoption testing
closely parallel the indications applied to children living
with their biological parents.83 The rationale for these rec-
ommendations rests on concerns that harms might come
to the child without sufficient benefit to balance the scales.
If such concerns are valid for children living with their bio-
logical parents, then the standards for genetic testing
should be the same for all children. The ‘‘principle of eq-
uity’’ articulates the idea that prospective adoptive parents
are entitled to no more information at the time of taking
custody of a child than the child’s birth parents could
obtain.84he American Journal of Human Genetics 97, 6–21, July 2, 2015 13
A countervailing argument has been raised to the princi-
ple of equity. It has been suggested that it is in the interest
of the child to be placed with families who are optimally
capable of taking care of their medical needs.85 Adoptive
parents are already subjected to additional scrutiny to
ensure that they have the capability to serve as suitable
parents.86 To some extent, the child’s background might
also influence these decisions. A commonly held view is
that it would disadvantage the child to be placed with
some adoptive parents and that even factors such as cul-
tural and ancestral education should be considered.
It is possible that a child with an untreatable genetic dis-
order would be better off with parents specifically chosen
because of their ability to deal with this difficult circum-
stance. An obvious objection is that knowledge of the dis-
order might so restrict the pool of willing parents that the
child is made ‘‘unadoptable.’’ Another concern is that
adults responsible for the placement of adoptive children
most likely do not have the specialized genetics knowledge
that would be required for assigning children to ‘‘matched’’
families.
Another argument for matching is that prospective,
adoptive parents’ interests would be harmed by failure of
the adoption agency to make the best possible choice of
home on the basis of the full range of relevant information
about the child. However, there is no assertion of a parallel
responsibility of the prospective parents to undergo
genetic testing themselves. The argument of matching cre-
ates the possibility that some parents might find them-
selves to be genetically unsuitable to adopt.
d The ASHG recommends that both children awaiting
adoption and adopted children be given the same
consideration in genetic testing as children living
with their biological parents. We endorse and affirm
the previous recommendations of the ASHG.
d All genetic testing of newborns and children in the
adoption process should be consistent with the tests
performed on all children of a similar age for the pur-
poses of diagnosis or of identifying appropriate pre-
vention strategies.
d Because the primary justification for genetic testing of
any child is a timely medical benefit to the child,
genetic testing of newborns and children in the adop-
tion process should be limited to testing for condi-
tions that manifest themselves during childhood or
for which preventivemeasures or therapies can be un-
dertaken during childhood.Consanguinity
Inbreeding, including first-degree relative relationships,
could be detected in genome-wide assays including but
not restricted to SNP genotyping, whole-exome
sequencing, andwhole-genome sequencing.87 It is possible
to find long segments of chromosomes lacking expected
heterozygous variation—called runs of homozygosity or14 The American Journal of Human Genetics 97, 6–21, July 2, 2015absence of heterozygosity (AOH). If AOH is confined to a
single chromosome, the cause could be a chromosome
replication or segregation abnormality (uniparental isodis-
omy [UPD]). In UPD, the person undergoing testing has
received identical copies of one parental homolog for part
or all of a chromosome. The length of the homozygous
segment will usually distinguish UPD from autozygosity—
identical chromosome segments inherited from themother
and father as a result of a recent shared ancestor. In contrast,
if there are multiple long AOH segments with AOH
involving many or all of the chromosomes, the most likely
explanation is that the parents are close biological relatives.
The ACMG has published guidelines for diagnostic labora-
tories to distinguish UPD from consanguinity.88 With the
accumulation of extensive genomic data in diverse human
populations, we can expect further refinement and
improved specificity in methods of interpreting tests.89
In some ways, detection of extensive AOH is a secondary
finding. The motivation for genetic testing might be to
detect a diagnostically important DNA copy-number ab-
normality or single-gene disorder. But the finding of
AOH cannot be considered purely incidental because
UPD detection is a formal reason for diagnostic testing.
UPD or autozygosity can be a necessary condition for
imprinting defects or homozygous recessive disorders.
Disclosure of the results should, therefore, be guided by
the same principles as those for other diagnostic testing.
The detection of extensive long segments of AOH is
most consistent with reproduction between close relatives.
In the absence of a history of assisted reproduction, this
implies incest. The central concern for practitioners is
the possibility of sexual abuse of a minor. Sexual relations
between close relatives are illegal in most jurisdictions, but
the specifics of the laws vary in how relatedness is speci-
fied.90 The detection of a consanguineous relationship by
itself does not engender a duty to report it to the author-
ities. Physician-patient confidentiality must be respected
in most circumstances. An important exception is the
circumstance in which the health-care provider suspects
that a child is being abused. Physicians are obligated to
report suspected child abuse without exception.
It does not necessarily follow that the possibility of
discovering information that could lead to a suspicion of
child abuse should be presented in pre-test counseling.
For most patients, this information will be irrelevant but
could cause unnecessary anxiety and could even lead to
the refusal to allow a diagnostic test.
d The ASHG recommends that laboratories adopt data
standards and analytical methods that allow reliable
detection of incest. Practitioners should develop pro-
cedures for casemanagementwhen genetic laboratory
results are consistent with incest involving a minor.
Practitioners have a duty to report suspected child
abuse.Health-care providers donothave a responsibil-
ity to report incest involving consenting adults, even
though this might be illegal in their jurisdiction.
Parentage
Misattributed parentage could be detected when biological
relatives undergo genetic testing. Genetic testing, and
especially genomic testing, of children and their parents
can lead to results inconsistent with the assumed social in-
heritance relationships. The most commonly encountered
problem is misattributed paternity. With estimated rates of
1%–10% from various studies, non-paternity is relatively
common and is therefore highly likely to be encountered
in routine practice and in research.91–93 However, with
the increased use of assisted reproduction, rare occurrences
of misattributed maternity have been described. Misattrib-
uted parentage (where neither the mother nor the father is
biologically related to the child), albeit very rare, would be
quickly recognized with many forms of modern genetic
testing. Clarifying the pattern of inheritance of pathogenic
variants is a key goal of genetic testing; therefore, it is rec-
ommended in all cases that evidence of segregation of
potentially disease-causing alleles and parental test results
be examined to conclusively demonstrate de novo
mutation.
Arguments in favor of full disclosure of paternity find-
ings center on issues of a patient’s right to know, avoiding
paternalism, and the duty of physicians to be truthful. A
broad answer to these concerns is that it is not possible
for either mothers or fathers to truly exercise their auton-
omy if the options are not presented before testing has
taken place. Given the intuition that there could be exten-
sive harm, health-care providers following a plan of non-
disclosure could be exercising prudence in avoiding inter-
ference in the family relationships.
Specific recommendations for the disclosure of misat-
tributed parentage have been made, but opinions ex-
pressed in the literature are diverse and unsettled.94
Although the mother and father (both social and biolog-
ical) have an undoubted stake in the outcome of parentage
information, there is an asymmetry of risk. Only the fidel-
ity of the mother is at stake in the test result. For this
reason, it is common practice to disclose only to the
mother. For example, the Institute of Medicine produced
a report advocating disclosure of misattributed paternity
only to the biological mother.71 This has been countered
with arguments pointing out that both the integrity of
the physician-patient relationship and professional re-
sponsibility involve both the mother and father.95 Inten-
tional deception is contrary to fundamental values in med-
ical practice. In her critique, Ross strongly advocated for
full disclosure to both parents. Although the risk is asym-
metric prior to testing, the post-test results involve both
the mother and father. Lack of disclosure to the father
could involve either misleading interpretations with
consequent misleading counseling or outright deception.
These are departures from standards of full disclosure,
non-directiveness, and respect for autonomy.
More recently, it has been suggested that information
about parentage should not be part of routine genetic
test reporting and counseling unless it is specifically re-Tquested by the parents in advance of the test. Arguing in
favor of such an approach, Palmor and Fiester conclude
that health-care professionals have no legitimate right to
decide about a matter with such high potential for harm
to so many individuals in both the close and extended
family.96 They suggest that providers inform clients that
although misattributed parentage could be detected in
the testing, it will not be disclosed to either the mother
or the father. They further argue that parents wishing to
investigate parentage should pursue specific testing.
Given the unsettled nature of the debate, it is essential
that health-care providers develop a consistent plan for
dealing with parentage and ancestry questions of all types.
Parents should be informed before the test is performed
about the risk of detection of misattributed parentage,
and as with other forms of incidental findings, pre-test
counseling should be provided. Because the risk in misat-
tributed paternity is asymmetric, an approach for pre-test
counseling could include confidentially informing the
mother of the potential detection of non-paternity.
d The ASHG recommends that parents be given infor-
mation about the possibility of detecting misattrib-
uted parentage during pre-test counseling. While
honoring their broad responsibility to be truthful
with patients and their families, we recommend
that health-care providers avoid disclosure of misat-
tributed parentage unless there is a clear medical
benefit that outweighs the potential harms.Record and Communication Issues
Quality clinical genetics practice begins and ends with
good communication, and evidence indicates that patients
value clear communication from medical providers.
Because of the complexity of the information, genetic
test results have the potential to be misunderstood and
to cause harm. Examples include NBS false-positive results,
over-interpretation of carrier status or variants of uncertain
significance, and the nuances of ‘‘negative’’ results in the
face of a suspected genetic disorder.
d The ASHG recommends that providers of pediatric ge-
netic testing have appropriate training and expertise
in the interpretation and communication of genetic
information.
d The ASHG recommends that diagnostic laboratories
develop reports that are detailed and accurate but
also facilitate comprehension by providers.
Communication of genetic test results in the pediatric
setting is complicated by the potentially long timeline of
transition from childhood to adulthood, during which par-
ents act as decision makers on behalf of the child, and the
differing capacity of individual children at different devel-
opment stages to participate in such decisions and to
contemplate the meaning of the results. Genetiche American Journal of Human Genetics 97, 6–21, July 2, 2015 15
information can also have important implications for sib-
lings and other family members.
d The ASHG recommends that genetic testing in chil-
dren should include a long-term communication
plan for all results, including consideration of who
should be involved in the communication of infor-
mation and the staging of information sharing on
the basis of age, maturity, and capacity to understand.
Unlike medical tests that measure temporary aspects of
an individual’s anatomy or physiology, genetic tests pro-
vide information of a permanent nature about an individ-
ual and potentially their family members. However, main-
taining knowledge of genetic results over long periods of
time can be challenging. Even though basic information
might be recalled (such as the fact that a genetic work-up
was performed), the specific details about childhood ge-
netic test results and their implications might not be accu-
rately remembered many years later. This loss of retention
severely impairs their subsequent utilization by clinicians,
patients, or patients’ family members and can lead to
unnecessary repeat genetic testing and thus a waste of re-
sources. Modern electronic medical records have the po-
tential to maintain information with much greater fidelity
over the lifespan of the individual.
d The ASHG recommends that standards be developed
for permanent storage of genetic data in electronic
health records or other secure electronic systems to
facilitate the provision of genetic information in pa-
tient portals.
d The ASHG also recommends the development of
mechanisms for sharing family history and genetic re-
sults with family members.
As genetic testing modalities become more comprehen-
sive and generate large amounts of raw data, genetic test re-
sults will challenge the current model of storing laboratory
results. Most genetic variation will be of unclear clinical
significance but might become interpretable over time
with continual advances in medical science. However, cur-
rent electronic medical records are not typically designed
to manage storage or re-analysis of genome-scale informa-
tion, and it is not clear whether it would be desirable for
them to do so. Recent federal regulations provide for labo-
ratory results to be the property of the patient, raising
questions about how much genomic information should
be placed in the medical record, particularly in the case
of genetic variation that does not have well-established
clinical implications. Furthermore, with some notable ex-
ceptions, a key limitation of the typical interface between
the clinical laboratory and the medical record is that it in-
volves a single instance of data transfer that does not
permit re-interpretation of genetic results over time.
d The ASHG recommends the development of uniform
guidelines to standardize medical-record capabilities16 The American Journal of Human Genetics 97, 6–21, July 2, 2015and management of interpreted results and raw ge-
netic sequence data.
d The ASHG also recommends developing novel
models for molecular laboratory and interpretive ser-
vices on the basis of prospects for the re-analysis of ge-
netic information over time.Professional Education
If health-care providers are to adhere successfully to the
recommendations in this report, they must have appro-
priate knowledge and skills related to genetic and genomic
testing, interpretation of test results, communication of re-
sults to patients and families, and basic genetic coun-
seling. In addition, the health-care system will require
adequate numbers of trained medical geneticists and ge-
netic counselors to assist in the role of specialty testing
and interpretation of results. With the expected expansion
of genetic and genomic testing, all health-care providers
will need (1) educational programs that target relevant sci-
entific, clinical, ethical, legal, and social topics and (2) sup-
port systems that address structural and systemic barriers
to the integration of genetic medicine into clinical
practice.
Providers’ Understanding of Genetic Medicine
Previous studies have clearly documented that health-care
providers have knowledge gaps that constitute a rate-
limiting step in the incorporation of genetics and geno-
mics into mainstream health care.97–99 Guttmacher
et al.97 and McInerney et al.98 summarized some of the
central deficiencies related to clinicians’ understanding of
genetic medicine as follows:
Misconceptions about genetics: many health-care
providers still believe that genetic medicine is
defined by rare, Mendelian disorders and circum-
scribed by pediatrics and obstetrics, when in fact ge-
netics increasingly is concerned with the common,
chronic diseases that are the daily focus for most
health professionals.
Lack of knowledge and confidence about genetics:
surveys of practicing health professionals demon-
strate a lack of basic knowledge about genetics and,
often, a lack of confidence to deal with genetics-
related issues that arise in the clinical setting.
Deficiencies in genetics education extend from the pre-
service training of most health-care professionals to post-
graduate internships, residency and fellowship training,
and continuing medical and professional education for
actively practicing health-care professionals. Notable
efforts exist in various organizations across the US to inte-
grate genetics and genomics into formal education and to
increase the genetics content of certifying exams.100–104
Many of those efforts are driven by the development of
competencies that focus on content knowledge and related
clinical skills.
Equally important is the challenge of training those
health-care providers currently in practice. A 2012 report
from the UK’s Human Genomics Strategy Group105 cap-
tures the situation concisely:
Ensuring that genomics is an integral part of initial
medical/health education and training will be an
important step towards developing the work force.
But for the next 15 years at least, the majority of staff
who will have to cope with the movement of geno-
mics into mainstream clinical work will be those
who are already trained and accredited. That is why
the bigger educational challenge is to close the skills
gap within the existing work force, via continuing
professional development (CPD) arrangement.
The highly diverse disciplines, clinical settings, and mo-
tivations reflected in this vast health-care work force will
require equally diverse educational approaches, all of
which must involve the end user from the initial planning
through implementation and evaluation.98 Again, some
good models for CPD are in place or in development in
the US, but implementation, evaluation, and scaling
from local to broader application remain as significant
challenges, and addressing them will require material
and personnel resources.106–108
Structural and Systemic Barriers
The practice model in health care evolves constantly, and
just as the development of antibiotics in the twentieth cen-
tury and medical imaging in the late twentieth and early
twenty-first centuries changed the practice of medicine,
genetics and genomics are changing medical practice
today. Education of practicing clinicians and the applica-
tion of new knowledge and skills highlight some of the sys-
temic challenges to incorporating genetic medicine into
health management, for example:
Lack of management and referral guidelines in ge-
netics and genomics: the paucity of evidence-based
guidelines related to genetic medicine, and the
slow dissemination of those that do exist, impede cli-
nicians’ attention to genetics and raise questions
about clinical utility.
A dearth of genetics professionals: the low numbers
of medical geneticists and genetic counselors in the
USA and elsewhere limit the provision of genetic ser-
vices directly and, furthermore, limit the extent to
which other providers have formal and informal ac-
cess to genetics expertise.109
Haga et al. reported that in a survey of US PCPs, ‘‘more
than half (53%) of respondents indicated they do not
have access to genetics expertise.’’ The authors of the study
suggest ‘‘a hybrid model of education and support for PCPs
and access to specialist consultation when needed.’’110
Hamilton et al., using diffusion of innovation theory andTfocusing on clinical genetic services in the Veterans’
Administration, have elaborated some of the factors that
promote or impede the integration of genetics into various
types of primary and specialist practice.111 In assessing fac-
tors such as complexity, compatibility with existing ser-
vices, and relative advantage (‘‘added value . when
compared to existing practice’’), the authors found that
study participants ‘‘indicated that benefits did not
outweigh the costs of genetic services,’’ and they conclude
that uptake of genetic services ‘‘by simple diffusion’’ will
not work. ‘‘Instead,’’ they assert, ‘‘adoption of clinical ge-
netic services will require development of targeted organi-
zational supports to strengthen the likelihood of adoption
and implementation.’’
Even these few examples demonstrate the complexity of
the challenges facing the education of health professionals
and the subsequent integration of genetics and genomics
into practice. Information does not equal education, espe-
cially when the objective is to change clinical behaviors
and improve patient outcomes.
Although it is not ASHG’s responsibility to direct change
in this complex system of formal and informal education
from pre-clinical training to continuing education, it can
help to promote change by supporting the recommenda-
tions below.
d ASHG recommends that the genetics community
work closely with appropriate educational institu-
tions, governing bodies, and professional societies to
develop and deliver programs that provide the knowl-
edge and skills health-care providers need to apply the
recommendations herein in their own practices.
d ASHG recommends that the introduction of genetics-
related content and case examples should emphasize
the extension of existing knowledge and skills and
should not portray genetics as a discipline that re-
quires wholly new approaches to clinical care.
d ASHG recommends that those developing educa-
tional programs be cognizant of the structural barriers
that impede the integration of genetic medicine—or
any other clinical innovation—into routine practice
and attempt to address those barriers in program con-
tent and implementation strategies.
d ASHG recommends that educational programs for
health-care providers include well-designed evalua-
tion plans that assess the efficacy of content, instruc-
tional approaches, and implementation strategies.
Evaluation plans should be in place before program
development begins and should reflect carefully
developed educational objectives and outcomes.
d Because a well-informed public presumably will make
better individual and collective decisions about the is-
sues elaborated in this report, the genetics commu-
nity should support efforts to improve public genetic
literacy and scientific literacy in general.
d The inevitable and significant increase in the number
and use of genetic tests will require more genetiche American Journal of Human Genetics 97, 6–21, July 2, 2015 17
18counselors and more genetically competent nurses,
physician assistants, and physicians. The ASHG rec-
ommends an increase in the number and size of
training programs and the provision of funds to sup-
port this expanding training infrastructure.Acknowledgments
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